Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder: Post hoc analyses of 3 randomized, controlled clinical trials

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 656-660

  Hoffmann, Vicki P ^a   Case, Michael ^a   Stauffer, Virginia L ^a   Jacobson, Jennie G ^a   Conley, Robert R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

antipsychotic agents; glucose; triglycerides; weight

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC PARAMETERS; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CHOLESTEROL; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; THIAZOLES; TIME FACTORS; TRIGLYCERIDES; WEIGHT GAIN;

EID: 78649370251     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181faf670     Document Type: Article

References (16)

1. Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879-1887.
2. Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006;26:157-162.
3. Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schiz Res. 2008;101:273-286.
4. Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837-1847.
5. Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:1535-1538.
6. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006;189:259-266.
7. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009;70:572-581.
8. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(suppl 18): 47-56.
9. Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry. 2007;68:1682-1690.
10. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65:510-517.
11. Kinon BJ, Stauffer VL, Kollack-Walker S, et al. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol. 2008;28:601-607.
12. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26:316-320.
13. Lipkovich I, Jacobson JG, Hardy TA, et al. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 2008, 8:78. Accessed at http://www.biomedcentral.com/ 1471-244X/8/78.
14. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27:596-601.
15. Grundy S, Becker D, Clark LT, et al. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. Volume NIH Publication No. 01-3670. Bethesda, MD: National Institutes of Health; 2001.
16. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schiz Bull. 2002;28:5-16.